Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24133999 | 1.00 | HSD11B1 (0.40) | HSD11B1HSD11B2CYP2C9DGAT1L3MBTL1 | |
| SCHEMBL3644747 | 0.89 | HSD11B1 (0.43) | HSD11B1HSD11B2DGAT1L3MBTL1PKM | |
| SCHEMBL28776246 | 0.84 | CYP2C9 (0.40) | HSD11B1CYP2C9L3MBTL1KDM4EHTT | |
| SCHEMBL19557168 | 0.81 | HSD11B1 (0.48) | HSD11B1CYP2C9L3MBTL1PKMKDM4E | |
| SCHEMBL19557166 | 0.81 | HSD11B1 (0.48) | HSD11B1CYP2C9L3MBTL1PKMKDM4E | |
| SCHEMBL12714 | 0.81 | HSD11B1 (0.48) | HSD11B1CYP2C9L3MBTL1PKMKDM4E | |
| SCHEMBL1844825 | 0.81 | HSD11B1 (0.40) | HSD11B1HSD11B2CYP2C9DGAT1L3MBTL1 | |
| SCHEMBL22131023 | 0.81 | HSD11B1 (0.43) | HSD11B1HSD11B2DGAT1L3MBTL1PKM | |
| SCHEMBL974023 | 0.81 | HSD11B1 (0.40) | HSD11B1HSD11B2CYP2C9DGAT1L3MBTL1 | |
| SCHEMBL24134002 | 0.81 | HSD11B1 (0.39) | HSD11B1HSD11B2CYP2C9L3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11640114-B2 | Compound, resin, photoresist composition and process for producing photoresist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-02 | — | — | US | disclosed |
| CN-107556244-B | Fused ring compound, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210255545-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-08-19 | — | — | US | disclosed |
| US-20200326625-A1 | COMPOUND, RESIN, PHOTORESIST COMPOSITION AND PROCESS FOR PRODUCING PHOTORESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-10-15 | — | — | US | disclosed |
| CN-107438611-B | fused ring compound, pharmaceutical composition and application thereof | SHANGHAI DE NOVO PHARMATECH CO.,LTD. (CN) | 2019-10-29 | — | — | CN | disclosed |
| WO-2019184919-A1 | ADAMANTANE-CONTAINING COMPOUND AND USE THEREOF IN TREATING CANCER | 成都海创药业有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-20190107778-A1 | SALT AND PHOTORESIST COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-11 | — | — | US | disclosed |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| EP-0732333-B1 | Indazolecarboxamides | LILLY CO ELI (US) | 2001-08-01 | — | — | EP | disclosed |
| US-5817676-A | 5-HT4 RECEPTOR ANTAGONISTS, CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5798367-A | ANTAGONIZE 5-HYDROXYTRYPTAMINE RECEPTOR IN GASTROINTESTINAL TRACT OR GENITOURINARY TRACT | ELI LILLY AND COMPANY (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | disclosed |
| CN-1183041-A | Indazolecarboxamides | LILLY CO ELI (US) | 1998-05-27 | — | — | CN | disclosed |
| US-5654320-A | SEROTONIN RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996033713-A1 | INDAZOLECARBOXAMIDES | ELI LILLY AND COMPANY (US) | 1996-10-31 | — | — | WO | disclosed |
| EP-0732333-A1 | Indazolecarboxamides | ELI LILLY AND COMPANY (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5395836-A | Adenosine A1 receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200326625-A1 | COMPOUND, RESIN, PHOTORESIST COMPOSITION AND PROCESS FOR PRODUCING PHOTORESIST PATTERN | HAX1, BRIX1, RXRA | HSD11B1 3373/4885HSD11B2 3734/4885CYP2C9 1426/4885 |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | HSD11B1 196/4885HSD11B2 127/4885CYP2C9 49/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | HSD11B1 196/4885HSD11B2 127/4885CYP2C9 49/4885 |
| US-20210255545-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | FGFR1, RER1, FGF1 | HSD11B1 88/4885HSD11B2 140/4885CYP2C9 1168/4885 |
| US-11640114-B2 | Compound, resin, photoresist composition and process for producing photoresist pattern | HAX1, BRIX1, RXRA | HSD11B1 3373/4885HSD11B2 3734/4885CYP2C9 1426/4885 |
| US-20190107778-A1 | SALT AND PHOTORESIST COMPOSITION CONTAINING THE SAME | CRY1, REN, SLC6A19 | HSD11B1 97/4885HSD11B2 205/4885CYP2C9 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.